KATTERJOHN: Closing the book on 30 years

Chris Katterjohn
February 27, 2010
Back to TopCommentsE-mailPrintBookmark and Share

Chris Katterjohn CommentaryIt’s a tall order to write a farewell column after 30 years.

How do you sum up three decades in 650 words? You don’t, really, but as I ponder the prospect, what comes up in me is a sense of gratitude: I’ve sat in a seat of privilege during my time at IBJ.

Privilege because my career here has given me so much.

First as managing editor, then as editor, and for the last 20 years as publisher, I’ve had a birds-eye view on a city that has transformed itself from a wanna-be to a bona-fide contender.

And I’ve been able to follow that story from what feels like an insider’s perspective every step of the way.

I’ve been at the heart of a newspaper that was started from scratch in a brand new niche and grew into not only a successful business, but also a respected, award-winning publication, viewed locally as an institution and nationally as one of the best.

As the only remaining member of the team that started IBJ, I feel my departure marks the end of an era, and the beginning of a new one. It’s been my privilege to help guide IBJ into adulthood.

And you know what? For the most part, this newspapering stuff is just plain fun. After 30 years, I still get jazzed when we find out about something big and break the story before anybody else does. I’ll miss that.

This job has also given me an education. Not only have I learned a lot about running this business, but I’ve learned a lot about all kinds of different businesses. Very few jobs provide that opportunity.

My role here also has been my gateway to community involvement—from city and chamber of commerce committees to not-for-profit boards—and to meeting people I otherwise would never have had the chance to meet.

And, for the most part, the folks I’ve met have been great.

Through our national business-journal trade group, I’ve met men and women from all over the country who get to do the same things in their communities that I’ve gotten to do in mine. Even better, many of these professional acquaintances have become dear friends.

Of course, if you’re lucky, the best part of any job is the people with whom you work. I couldn’t have asked for a better group of colleagues, two of whom I’ve worked with more than 25 years.

And, finally, I offer thanks to our readers and advertisers. We obviously wouldn’t have a newspaper or our jobs if it weren’t for you. Thank you all for your support over the years.

People have reminded me often about the power of newspapers. We understand that the printed word not only reports reality but also creates it for our readers. You have to trust that what you read is true.

That is a responsibility we have never taken lightly. We have worked hard to earn your trust and keep it. Sure, we have made mistakes over the years, but we have never intentionally abused the power we have.

There have been lots of high points and a few low ones.

I will always remember the excitement I felt when I first walked in the door, six weeks before the first IBJ hit the street. I will always remember the excitement I felt just last October when we broke the Tim Durham story.

And there are a million “I-will-always-remembers” in between.

But as we all know, there comes a time to move on, and this is my time. My plan is take a few months off, then search out another opportunity. If I can find one that offers a fraction of the fun and satisfaction this one has, I’ll be a happy man.

This has been my privilege. Thank you for everything.•


To comment on this column, send e-mail to tharton@ibj.com. To reach Chris Katterjohn, send e-mail to ckatterjohn@indy.rr.com.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

  2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

  3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

  4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

  5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?